Another IPO frenzy? Two US biotechs head to Hong Kong for a public market debut

Two US-based biotechs, Stealth BioTherapeutics and AOBiome, have joined the queue to apply for an IPO in Hong Kong — a first since the city’s exchange changed its rules late April to attract pre-revenue drugmakers.